COMPARE · Data as of August 24, 2026
ALNY vs REGN
Verdict: Side-by-side breakdown using the Bull Rankings model. ALNY scored 74.9, REGN scored 64.0 — ALNY leads.
Compare another set
ALNY
Alnylam Pharmaceuticals, Inc.
74.9
$240.43 · $32.2B
fundamentals as of
Score gap
10.9
ALNY leads
REGN
Regeneron Pharmaceuticals, Inc.
64
$835.34 · $86.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- CheapestREGN20.7x
- Fastest growthALNY+65.2%
- Strongest balance sheetREGN0.09
- Highest qualityALNY67 / 100
Side by side · every name on one set of axes
Growth against the P/E multiple. Up and to the right is cheaper and faster — the quality-growth idea in one picture. Points beyond the axis are pinned to the edge and marked off-scale rather than allowed to compress everything else.
The model, pillar by pillar (0–100 each)
ALNY
stronger →← stronger
REGN
67
Qualityreturns · margins · balance sheet
66
99
Growthrevenue & earnings expansion
79
64
Valuevaluation vs sector peers
50
ALNY is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ALNY
REGN
$465mC
FCF
$3.8bB
+65.2%A
Rev
+9.3%B
2.21D
D/E
0.09B+
41.9xC
P/E
20.7xB+
0.45A
PEG
1.38B
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
ALNY
REGN
194% above
Price vs fair valuelower is cheaper
24% above
~44%/yr
Growth the price implies10-yr FCF · lower = less priced in
~14%/yr
-74%
1-yr DCF upside
-29%
-66%
5-yr DCF upside
-19%
-49%
10-yr DCF upside
-3%
These two disagree on this pair: the Value pillar ranks cheapness against sector peers, while price-vs-fair-value is an absolute read. A name can be the better value in its sector and still the dearer one on cash flows.
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ALNY
Why this score
- Diluting shareholders
REGN
Why this score
- Diluting shareholders
The companies
ALNYAlnylam Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $32.2b. Down 51% from 52-week high of $495.55 — deep drawdown territory. Revenue growing +65% — in hypergrowth territory. PEG 0.45 — paying under fair value for the growth rate. 26 sell-side analysts rate this a Buy with a mean 1-yr target of $370.20 (implying +54% upside).
Moat
Net margin 20% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 54% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
D/E 2.21 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer. Down 51% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up. Trailing P/E 42x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates.
REGNRegeneron Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $86.0b. Trading near 52-week high of $847.00 — momentum setup, limited technical margin of safety. 27 sell-side analysts rate this a Buy with a mean 1-yr target of $840.43 (implying +1% upside).
Moat
Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 14% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $86.0b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ALNY and REGN diverge
On the headline score the gap is 10.9 points in favor of ALNY. The widest single difference is Growth, where ALNY leads by 19.9 points.
- GrowthALNY 98.5 · REGN 78.6ALNY +19.9
- ValueALNY 63.8 · REGN 50.4ALNY +13.4
- QualityALNY 66.8 · REGN 66.3level
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.